| Previous Close | 0.3700 |
| Open | 0.0000 |
| Bid | 0.0000 x |
| Ask | 0.0000 x |
| Day's Range | 0.0000 - 0.0000 |
| 52 Week Range | |
| Volume | 0 |
| Avg. Volume | 90,590 |
| Market Cap | 16.64M |
| Beta | 0.69 |
| PE Ratio (TTM) | -7.53 |
| EPS (TTM) | -0.05 |
| Earnings Date | N/A |
| Dividend & Yield | 0.00 (0.00%) |
| Ex-Dividend Date | 2015-12-30 |
| 1y Target Est | 14.00 |
Capital Cube•2 months agoEnzon Pharmaceuticals, Inc. :ENZN-US: Earnings Analysis: Q1, 2017 By the Numbers : May 18, 2017
Categories: Yahoo FinanceGet free summary analysis Enzon Pharmaceuticals, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Enzon Pharmaceuticals, Inc. – Nektar Therapeutics, Amgen Inc., Enanta Pharmaceuticals, Inc., Pfizer Inc., Merck & Co., Inc., Valeant Pharmaceuticals International Inc, XOMA Corporation, SciClone Pharmaceuticals, Inc., Gilead Sciences, ... Read more (Read more...)
Capital Cube•4 months agoEnzon Pharmaceuticals, Inc. :ENZN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 28, 2017
Categories: Yahoo Finance Get free summary analysis Enzon Pharmaceuticals, Inc. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of Enzon Pharmaceuticals, Inc. – Nektar Therapeutics, Amgen Inc., Enanta Pharmaceuticals, Inc., Pfizer Inc., Merck & Co., Inc., Valeant Pharmaceuticals International Inc, XOMA Corporation, SciClone Pharmaceuticals, Inc. and Gilead ... Read more (Read more...)
GuruFocus.com•8 months agoCarl Icahn Takes 15% Stake in Enzon Pharmaceuticals
Activist investor continues his interest in penny stock
